Department of Orthopaedic Surgery, University Hospital Tuebingen, Tuebingen, Germany.
BMC Musculoskelet Disord. 2012 Sep 25;13:187. doi: 10.1186/1471-2474-13-187.
Possible immunization to blood group or other antigens and subsequent inhibition of remodeling or incorporation after use of untreated human bone allograft was described previously. This study presents the immunological, clinical and radiological results of 30 patients with acetabular revisions using fresh frozen non-irradiated bone allograft.
AB0-incompatible (donor-recipient) bone transplantation was performed in 22 cases, Rh(D) incompatible transplantation in 6 cases. The mean follow up of 23 months included measuring Harris hip score and radiological examination with evaluation of remodeling of the bone graft, implant migration and heterotopic ossification. In addition, all patients were screened for alloimmunization to Rh blood group antigens.
Compared to the whole study group, there were no differences in clinical or radiological measurements for the groups with AB0- or Rh(D)-incompatible bone transplantation. The mean Harris Hip Score was 80.6. X-rays confirmed total remodeling of all allografts with no acetabular loosening. At follow up, blood tests revealed no alloimmunization to Rh blood group donor antigens.
The use of fresh frozen non-irradiated bone allograft in acetabular revision is a reliable supplement to reconstruction. The risk of alloimmunization to donor-blood group antigens after AB0- or Rh-incompatible allograft transplantation with a negative long-term influence on bone-remodeling or the clinical outcome is negligible.
先前有报道称,未处理的人同种异体骨移植后,可能会对血型或其他抗原产生免疫反应,并随后抑制其重塑或吸收。本研究介绍了 30 例使用新鲜冷冻未辐照同种异体骨移植进行髋臼翻修患者的免疫、临床和影像学结果。
在 22 例病例中进行了 ABO 不相容(供体-受体)骨移植,在 6 例病例中进行了 Rh(D)不相容移植。23 个月的平均随访包括测量 Harris 髋关节评分和影像学检查,评估骨移植物的重塑、植入物迁移和异位骨化。此外,所有患者均进行了 Rh 血型抗原同种免疫筛选。
与整个研究组相比,AB0 或 Rh(D)不相容骨移植组在临床或影像学测量方面没有差异。Harris 髋关节评分为 80.6。X 射线证实所有同种异体移植物均完全重塑,无髋臼松动。随访时,血液检查未发现对 Rh 血型供体抗原的同种免疫。
在髋臼翻修中使用新鲜冷冻未辐照同种异体骨移植是一种可靠的重建补充方法。AB0 或 Rh 不相容同种异体移植后对供体血型抗原产生同种免疫的风险可以忽略不计,不会对骨重塑或临床结果产生长期负面影响。